SB-REG-CORTO – innovative cell therapy for osteoarthritis in dogs

Product description

SB-REG-CORTO is an innovative veterinary candidate for a biological medicine developed by Sanford Biotech on the basis of its own research and preclinical studies co-financed by the Tekla Plus grant programme and scientific publications, classified as a veterinary advanced therapy medicinal product (vATMP) for dogs. The preparation will be available in a deep-frozen, sterile form, ready for administration immediately after thawing in an ‘off the shelf’ formula.

Application

Our medicine has been designed to treat chronic joint inflammation in dogs, particularly in the early and moderate stages of degenerative changes (osteoarthritis), manifested by pain, lameness, stiff gait and reduced physical activity. Osteoarthritis (OA) is one of the most common causes of chronic pain in dogs – according to data from the Animal Health Monitoring Systems Programme, over 20% of the dog population in the USA suffers from it, and as many as two-thirds of dogs over the age of 7 show symptoms of OA.

Key benefits

  • Reduction of inflammation in the joint and periarticular tissues.

    Relief of pain and lameness, improving the dog's quality of life.

    Support for cartilage regeneration and joint homeostasis.

    Alternative to long-term use of NSAIDs/steroids

    Convenient logistics: off-the-shelf product (ready for immediate use after thawing)

How it works

The active substance is a suspension of live, allogeneic mesenchymal stem cells (MSCs) derived from adipose tissue, intended for intra-articular injection. The mechanism of action of MSCs is based on their strong immunomodulatory properties, which reduce inflammation within the joint, alleviate pain and activate the natural regenerative processes of joint cartilage. As a result, SB-REG-CORTO not only alleviates symptoms, but also acts causally, supporting the reconstruction of damaged tissues.

Advantages over standard therapies

Compared to standard therapies based on non-steroidal and steroidal anti-inflammatory drugs, which mainly treat symptoms and can cause numerous side effects (e.g. Cushing's syndrome, stomach ulcers, liver disease), SB-REG-CORTO offers greater efficacy and safety. As a biological drug, it is a modern alternative in the treatment of inflammatory diseases, especially in large, obese and older dogs, which are most at risk of developing OA.

 Note to investors

SB-REG-CORTO fits into the segment of veterinary biological therapies with high barriers to entry and growing market potential. It is estimated that there are over 7 million dogs in Poland and over 90 million across Europe. Osteoarthritis affects up to 20% of adult dogs, including two-thirds over the age of seven, which means millions of potential patients requiring modern therapeutic solutions. Thanks to its off-the-shelf formula and allogeneic MSC stem cells, the product offers high scalability, faster clinical adoption and positioning in the premium segment. According to analyses, the market for biological therapies for pets in Europe could reach a value of several billion euros per year, with a growth rate exceeding 10% CAGR. SB-REG-CORTO represents an attractive market opportunity, in line with the global trend of humanisation of pets.

Our publications

- Stanaszek L. i in. Cells (2021): doi:10.3390/cells10112968
- Malysz-Cymborska I. i in. Scientific Reports (2021): doi:10.1038/s41598-021-85820-3
- Klimczak A. i in. Cell Transplantation (2019): doi:10.1177/0963689719848355
- Skwarcz S. i in. Polish J. Vet. Sci. (2019): doi:10.24425/pjvs.2019.127077, doi:10.24425/pjvs.2019.127092